1
|
Zhang Q, Liu J, Duan H, Li R, Peng W, Wu C. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res 2022; 34:43-63. [PMID: 35024180 PMCID: PMC8655139 DOI: 10.1016/j.jare.2021.06.023] [Citation(s) in RCA: 228] [Impact Index Per Article: 114.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 06/09/2021] [Accepted: 06/29/2021] [Indexed: 12/14/2022] Open
Abstract
Introduction Recently, Nrf2/HO-1 has received extensive attention as the main regulatory pathway of intracellular defense against oxidative stress and is considered an ideal target for alleviating endothelial cell (EC) injury. Objectives This paper aimed to summarized the natural monomers/extracts that potentially exert protective effects against oxidative stress in ECs. Methods A literature search was carried out regarding our topic with the keywords of “atherosclerosis” or “Nrf2/HO-1” or “vascular endothelial cells” or “oxidative stress” or “Herbal medicine” or “natural products” or “natural extracts” or “natural compounds” or “traditional Chinese medicines” based on classic books of herbal medicine and scientific databases including Pubmed, SciFinder, Scopus, the Web of Science, GoogleScholar, BaiduScholar, and others. Then, we analyzed the possible molecular mechanisms for different types of natural compounds in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. In addition, perspectives for possible future studies are discussed. Results These agents with protective effects against oxidative stress in ECs mainly include phenylpropanoids, flavonoids, terpenoids, and alkaloids. Most of these agents alleviate cell apoptosis in ECs due to oxidative stress, and the mechanisms are related to Nrf2/HO-1 signaling activation. However, despite continued progress in research on various aspects of natural agents exerting protective effects against EC injury by activating Nrf2/HO-1 signaling, the development of new drugs for the treatment of atherosclerosis (AS) and other CVDs based on these agents will require more detailed preclinical and clinical studies. Conclusion Our present paper provides updated information of natural agents with protective activities on ECs against oxidative stress by activating Nrf2/HO-1. We hope this review will provide some directions for the further development of novel candidate drugs from natural agents for the treatment of AS and other CVDs.
Collapse
Key Words
- 7-HMR, (−)-7(S)-hydroxymatairesinol
- ADH, andrographolide
- AGE, advanced glycation end product
- AMP, Athyrium Multidentatum
- APV, aqueous extracts of Prunella Vulgaris
- ARE, antioxidant reaction elements
- AS, atherosclerosis
- ASD-IV, Astragaloside IV
- ASP, Angelica sinensis polysaccharide
- ASTP, Astragalus polysacharin
- Akt, protein kinase B
- Ang, Angiotensin
- ApoE, apolipoprotein E
- Atherosclerosis
- BAECs, bovine artery endothelial cells
- BBR, Berberine
- BITC, benzyl isothiocyanate
- C3G, Cyanidin-3-O-glucoside
- CINM, Cinnamaldehyde
- CNC, Cap'n'collar
- CREB, cAMP-response element binding protein
- CVDs, cardiovascular diseases
- CVRF, cardiovascular risk factors
- DMY, Dihydromyricetin
- ECC, (−)-Epicatechin
- ECs, endothelial cells
- EGCG, epigallocatechin-3-O-gallate
- ERK, extracellular regulated protein kinases
- ET, endothelin
- EXS, Xanthoceras sorbifolia
- FFA, Fatty Acids
- GPx, Glutathione peroxidase
- GSD Rg1, Ginsenoside Rg1
- GTE, Ganoderma tsugae extracts
- Gau A, Glaucocalyxin A
- HAMS, human anthocyanin medicated serum
- HG, high glucose
- HIF-1, Hypoxia-inducible factor 1
- HO-1, heme oxygenase
- HUVECs, human umbilical vein endothelial cells
- HXC, Huoxue capsule
- Hcy, Homocysteine
- Herbal medicine
- ICAM, intercellular adhesion molecule
- IL, interleukin
- KGRE, extracts of KGR
- KRG, Korean red ginseng
- Keap1, kelch-like epichlorohydrin-related proteins
- LWDH, Liuwei-Dihuang pill
- MA, maslinic acid
- MAPKK, mitogen-activated protein kinase kinase
- MAPKs, mitogen-activated protein kinases
- MCGA3, 3-O-caffeoyl-1-methylquinic acid
- MCP-1, monocyte chemotactic protein 1
- MMPs, matrix metalloproteinases
- Molecular mechanism
- NAF, Nepeta Angustifolia
- NF-κB, nuclear factor kappa-B
- NG, naringenin
- NQO1, NAD(P)H: quinone oxidoreductase
- Nrf2, nuclear factor erythroid-2 related factor 2
- Nrf2/HO-1 signaling
- OA, Oleanolic acid
- OMT, Oxymatrine
- OX-LDL, oxidized low density lipoprotein
- Oxidative stress
- PA, Palmitate
- PAA, Pachymic acid
- PAI-1, plasminogen activator Inhibitor-1
- PEITC, phenethyl isocyanate
- PI3K, phosphatidylinositol 3 kinase
- PKC, protein kinase C
- PT, Pterostilbene
- RBPC, phenolic extracts derived from rice bran
- ROS, reactive oxygen species
- SAL, Salidroside
- SFN, sulforaphane
- SMT, Samul-Tang Tang
- SOD, superoxide dismutase
- Sal B, salvianolic acid B
- SchB, Schisandrin B
- TCM, traditional Chinese medicine
- TNF, tumor necrosis factor
- TXA2, Thromboxane A2
- TrxR1, thioredoxin reductase-1
- US, uraemic serum
- VA, Vanillic acid
- VCAM, vascular cell adhesion molecule
- VEC, vascular endothelial cells
- VEI, vascular endothelial injury
- Vascular endothelial cells
- XAG, xanthoangelol
- XXT, Xueshuan Xinmaining Tablet
- Z-Lig, Z-ligustilide
- eNOS, endothelial NO synthase
Collapse
Affiliation(s)
- Qing Zhang
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China
| | - Jia Liu
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China
| | - Huxinyue Duan
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China
| | - Ruolan Li
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China
| | - Wei Peng
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China
| | - Chunjie Wu
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, PR China
| |
Collapse
|
2
|
Yoneda T, Hiasa M, Okui T, Hata K. Sensory nerves: A driver of the vicious cycle in bone metastasis? J Bone Oncol 2021; 30:100387. [PMID: 34504741 PMCID: PMC8411232 DOI: 10.1016/j.jbo.2021.100387] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2021] [Revised: 08/17/2021] [Accepted: 08/18/2021] [Indexed: 12/04/2022] Open
Abstract
Bone is one of the preferential target organs of cancer metastasis. Bone metastasis is associated with various complications, of which bone pain is most common and debilitating. The cancer-associated bone pain (CABP) is induced as a consequence of increased neurogenesis, reprogramming and axonogenesis of sensory nerves (SNs) in harmony with sensitization and excitation of SNs in response to the tumor microenvironment created in bone. Importantly, CABP is associated with increased mortality, of which precise cellular and molecular mechanism remains poorly understood. Bone is densely innervated by autonomic nerves (ANs) (sympathetic and parasympathetic nerves) and SNs. Recent studies have shown that the nerves innervating the tumor microenvironment establish intimate communications with tumors, producing various stimuli for tumors to progress and disseminate. In this review, our current understanding of the role of SNs innervating bone in the pathophysiology of CABP will be overviewed. Then the hypothesis that SNs facilitate cancer progression in bone will be discussed in conjunction with our recent findings that SNs play an important role not only in the induction of CABP but also the progression of bone metastasis using a preclinical model of CABP. It is suggested that SNs are a critical component of the bone microenvironment that drives the vicious cycle between bone and cancer to progress bone metastasis. Suppression of the activity of bone-innervating SNs may have potential therapeutic effects on the progression of bone metastasis and induction of CABP.
Collapse
Key Words
- AN, autonomic nerve
- BDNF, brain-derived neurotrophic factor
- BMP, bone morphogenetic protein
- BMSC, bone marrow stromal cells
- Bone microenvironment
- CABP, cancer-associated bone pain
- CALCRL, calcitonin receptor-like receptor
- CAP, cancer-associated pain
- CCL2, C–C motif chemokine 2
- CGRP, calcitonin gene-related peptide
- CNS, central nervous system
- COX, cyclooxygenase
- CREB, cyclic AMP-responsive element-binding protein
- CRPC, castration-resistant prostate cancer
- CXCL1, C-X-C Motif Chemokine Ligand 1
- CXCL2, C-X-C Motif Chemokine Ligand 2
- Cancer-associated bone pain
- DRG, dorsal root ganglion
- ERK1/2, extracellular receptor kinase ½
- G-CSF, granulocyte colony-stimulating factor
- GDNF, glial-derived neurotrophic factor
- HGF, hepatocyte growth factor
- HIF-1α, hypoxia-inducible transcription factor-1α
- HMGB-1, high mobility group box-1
- HSCs, hematopoietic stem cells
- HUVECs, human umbilical vein endothelial cells
- IL-1β, interleukin 1β
- MM, multiple myeloma
- MOR, mu-opioid receptor
- NE, norepinephrine
- NGF, nerve growth factor
- NI, nerve invasion
- NPY, neuropeptide Y
- NSAIDs, nonsteroidal anti-inflammatory drugs
- Nociceptors
- OA, osteoarthritis
- OPG, osteoprotegerin
- PACAP, pituitary adenylate cyclase-activating peptide
- PD-1, programmed cell death-1
- PD-L1, programmed death-ligand 1
- PDAC, pancreatic ductal adenocarcinoma
- PGE2, prostaglandin E2
- PNI, perineural invasion
- PanIN, pancreatic intraepithelial neoplasia
- Perineural invasion
- RAGE, receptor for advanced glycation end products
- RAMP1, receptor activity modifying protein 1
- RANKL, receptor activator of NF-κB ligand
- RTX, resiniferatoxin
- SN, sensory nerves
- SP, substance P
- SRE, skeletal-related event
- Sensory nerves
- TGFβ, transforming growth factor β
- TNFα, tumor necrosis factor α
- TRPV1
- TrkA, tyrosine kinase receptor type 1
- VEGF, vascular endothelial growth factor
- VIP, vasoactive intestinal peptide
- a3V-H+-ATPase, a3 isoform vacuolar proton pump
Collapse
Affiliation(s)
- Toshiyuki Yoneda
- Department of Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan
| | - Masahiro Hiasa
- Department of Biomaterials and Bioengineerings, University of Tokushima Graduate School of Dentistry, Tokushima, Japan
| | - Tatsuo Okui
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Kenji Hata
- Department of Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan
| |
Collapse
|
3
|
Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B 2021; 11:2726-2737. [PMID: 34589393 PMCID: PMC8463276 DOI: 10.1016/j.apsb.2021.01.004] [Citation(s) in RCA: 66] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 10/26/2020] [Accepted: 11/03/2020] [Indexed: 02/06/2023] Open
Abstract
Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development.
Collapse
Key Words
- ADAMs, adisintegrin and metalloproteases
- AJ, adherens junctions
- Antagonists
- CAFs, cancer-associated fibroblasts
- CAR, chimeric antigen receptor
- CRC, colorectal cancer
- CSC, cancer stem cell
- Clinical trial
- ECM, extracellular matrix
- EGFR, epidermal growth factor receptor
- EMT, epithelial–mesenchymal transition
- ERK, extracellular regulated kinase
- Extracellular matrix
- FAK, focal adhesion kinase
- FDA, U.S. Food and Drug Administration
- HIF-1α, hypoxia-inducible factor-1α
- HUVECs, human umbilical vein endothelial cells
- ICAMs, intercellular adhesion molecules
- IGFR, insulin-like growth factor receptor
- IMD, integrin-mediated death
- Integrins
- JNK, c-Jun N-terminal kinase 16
- MAPK, mitogen-activated protein kinase
- MMP2, matrix metalloprotease 2
- NF-κB, nuclear factor-κB
- NSCLC, non-small cell lung cancer
- PDGFR, platelet-derived growth factor receptor
- PI3K, phosphatidylinositol 3-kinase
- RGD, Arg-Gly-Asp
- RTKs, receptor tyrosine kinases
- SAPKs, stress-activated MAP kinases
- SDF-1, stromal cell-derived factor-1
- SH2, Src homology 2
- STAT3, signal transducer and activator of transcription 3
- TCGA, The Cancer Genome Atlas
- TICs, tumor initiating cells
- TNF, tumor necrosis factor
- Targeted drug
- Tumor progression
- VCAMs, vascular cell adhesion molecules
- VEGFR, vascular endothelial growth factor receptor
- mAb, monoclonal antibodies
- sdCAR-T, switchable dual-receptor CAR-engineered T
- siRNA, small interference RNA
- uPA, urokinase-type plasminogen activator
Collapse
|
4
|
Liu J, Ren L, Li S, Li W, Zheng X, Yang Y, Fu W, Yi J, Wang J, Du G. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B 2021; 11:2783-2797. [PMID: 34589397 PMCID: PMC8463268 DOI: 10.1016/j.apsb.2021.01.001] [Citation(s) in RCA: 194] [Impact Index Per Article: 64.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 08/30/2020] [Accepted: 10/12/2020] [Indexed: 02/07/2023] Open
Abstract
Exosomes are cell-derived nanovesicles with diameters from 30 to 150 nm, released upon fusion of multivesicular bodies with the cell surface. They can transport nucleic acids, proteins, and lipids for intercellular communication and activate signaling pathways in target cells. In cancers, exosomes may participate in growth and metastasis of tumors by regulating the immune response, blocking the epithelial-mesenchymal transition, and promoting angiogenesis. They are also involved in the development of resistance to chemotherapeutic drugs. Exosomes in liquid biopsies can be used as non-invasive biomarkers for early detection and diagnosis of cancers. Because of their amphipathic structure, exosomes are natural drug delivery vehicles for cancer therapy.
Collapse
Key Words
- ABCA3, ATP-binding cassette transporter A3
- APCs, antigen-presenting cells
- Biomarkers
- CAFs, cancer-associated fibroblasts
- CCRCC, clear-cell renal cell carcinoma
- CD-UPRT, cytosine deaminase-uracil phosphoribosyltransferase
- CDH3, cadherin 3
- CRC, colorectal cancer
- DC, dendritic cells
- DEXs, DC-derived exosomes
- DLBCL, diffuse large B-cell lymphoma
- DNM3, dynamin 3
- Del-1, developmental endothelial locus-1
- Drug delivery
- Drug resistance
- ECM, extracellular matrix
- EMT, epithelial–mesenchymal transition
- ESCRT, endosomal sorting complex required for transport
- Exosomes
- GPC1, glypican-1
- HA, hyaluronic acid
- HCC, hepatocellular carcinoma
- HIF1, hypoxia-inducible factor 1
- HTR, hormone therapy-resistant
- HUVECs, human umbilical vein endothelial cells
- ILVs, intraluminal vesicles
- MDSCs, myeloid-derived suppressor cells
- MIF, migration inhibitory factor
- MSC, mesenchymal stem cells
- MVB, multivesicular body
- NKEXOs, natural killer cell-derived exosomes
- NNs, nanoparticles
- NSCLC, non-small cell lung cancer
- PA, phosphatidic acid
- PCC, pheochromocytoma
- PD-L1, programmed cell death receptor ligand 1
- PDAC, pancreatic ductal adenocarcinoma
- PGL, paraganglioma
- PI, phosphatidylinositol
- PS, phosphatidylserine
- PTRF, polymerase I and transcript release factor
- RCC, renal cell carcinoma
- SM, sphingomyelin
- SNARE, soluble NSF-attachment protein receptor
- TEX, tumor-derived exosomes
- TSG101, tumor susceptibility gene 101
- Tumor immunity
- Tumor metastasis
- circRNAs, circular RNAs
- dsDNA, double stranded DNA
- hTERT, human telomerase reverse transcriptase
- lamp2b, lysosome-associated membrane glycoprotein 2b
- lncRNAs, long non-coding RNAs
- miRNA, microRNA
- mtDNA, mitochondrial DNA
- ncRNA, non-coding RNAs
Collapse
Affiliation(s)
- Jinyi Liu
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Liwen Ren
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Sha Li
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Wan Li
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Xiangjin Zheng
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Yihui Yang
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Weiqi Fu
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Jie Yi
- Department of Clinical Laboratory, Peking Union Medical College Hospital, Beijing 100730, China
| | - Jinhua Wang
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| | - Guanhua Du
- The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China
- Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
| |
Collapse
|
5
|
Osaka M, Deushi M, Aoyama J, Funakoshi T, Ishigami A, Yoshida M. High-Fat Diet Enhances Neutrophil Adhesion in LDLR-Null Mice Via Hypercitrullination of Histone H3. ACTA ACUST UNITED AC 2021; 6:507-523. [PMID: 34222722 PMCID: PMC8246031 DOI: 10.1016/j.jacbts.2021.04.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 04/06/2021] [Accepted: 04/07/2021] [Indexed: 12/21/2022]
Abstract
Neutrophil adhesion on the atheroprone femoral artery of high-fat diet-fed low-density lipoprotein receptor-null mice was enhanced more than in wild-type mice. The inhibition of histone H3 citrullination of neutrophils reversed the enhancement of neutrophil adhesion, suggesting that hypercitrullination contributes to enhanced neutrophil adhesion. Furthermore, pemafibrate reduced the citrullination of histone H3 in these mice. Therefore, the hypercitrullination of histone H3 in neutrophils contributes to atherosclerotic vascular inflammation.
Collapse
Key Words
- BM, bone marrow
- BW, body weight
- DNaseI, deoxyribonuclease I
- GM-CSF, granulocyte-macrophage colony-stimulating factor
- HFD, high-fat diet
- HUVECs, human umbilical vein endothelial cells
- IVM, intravital microscopy
- LDLR, low-density lipoprotein receptor
- LysM, lysosome M
- MPO, myeloperoxidase
- NC, normal chow
- NE, neutrophil elastase
- NET, neutrophil extracellular trap
- PAD4, peptidylarginine deiminase 4
- PPAR, peroxisome proliferator-activated receptor
- TC, total cholesterol
- TDFA, N-acetyl-l-threonyl-l-α-aspartyl-N5-(2-fluoro-1-iminoethyl)-l-ornithinamide trifluoroacetate salt
- TG, triglyceride
- citrullination
- cxcl1
- eGFP, enhanced green fluorescent protein
- in vivo imaging
- neutrophil
- vascular inflammation
- wt, wild type
Collapse
Affiliation(s)
- Mizuko Osaka
- Department of Life Science and Bioethics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.,Department of Nutrition and Metabolism in Cardiovascular Disease, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Michiyo Deushi
- Department of Life Science and Bioethics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Jiro Aoyama
- Department of Life Science and Bioethics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Tomoko Funakoshi
- Research Team for Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.,Department of Physiology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Akihito Ishigami
- Research Team for Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
| | - Masayuki Yoshida
- Department of Life Science and Bioethics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
6
|
Yao Y, Liu Z, Zhao M, Chen Z, Li P, Zhang Y, Wang Y, Zhao C, Long C, Chen X, Yang J. Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy. Acta Pharm Sin B 2020; 10:1453-1475. [PMID: 32963943 PMCID: PMC7488503 DOI: 10.1016/j.apsb.2020.04.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2019] [Revised: 03/18/2020] [Accepted: 03/26/2020] [Indexed: 02/05/2023] Open
Abstract
Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great success in recent years. In this study, we presented the design, synthesis, target identification, molecular mechanism, pharmacodynamics (PD) and pharmacokinetics (PK) research of a novel triple-angiokinase inhibitor WXFL-152. WXFL-152, identified from a series of 4-oxyquinoline derivatives based on a structure-activity relationship study, inhibited the proliferation of vascular endothelial cells (ECs) and pericytes by blocking the angiokinase signals VEGF/VEGFR2, FGF/FGFRs and PDGF/PDGFRβ simultaneously in vitro. Significant anticancer effects of WXFL-152 were confirmed in multiple preclinical tumor xenograft models, including a patient-derived tumor xenograft (PDX) model. Pharmacokinetic studies of WXFL-152 demonstrated high favourable bioavailability with single-dose and continuous multi-dose by oral administration in rats and beagles. In conclusion, WXFL-152, which is currently in phase Ib clinical trials, is a novel and effective triple-angiokinase inhibitor with clear PD and PK in tumor therapy.
Collapse
Key Words
- ATCC, American Type Culture Collection
- AUC, area under the plasma concentration–time curve
- Anti-angiogenesis therapy
- CE, collision energy
- CL, systemic clearance
- Cmax, maximum plasma concentration
- Drug synthesis
- EC, vascular endothelial cell
- ECM, endothelial cell medium
- ERKs, extracellular signal-regulated kinases
- FGF, fibroblast growth factor
- FGFRs, fibroblast growth factor receptors
- HBVPs, human brain vascular pericytes
- HUVECs, human umbilical vein endothelial cells
- IC50, half maximal inhibitory concentration
- IHC, immunohistochemistry
- LC–MS, liquid chromatography mass spectrometry
- LLOQ, lower limit of quantification
- MRM, multiple reaction monitoring
- MsOH, methane sulfonic acid
- Multi-angiokinase inhibitor
- NMR, nuclear magnetic resonance
- PD, pharmacodynamics
- PDB, protein data bank
- PDGF, platelet-derived growth factor
- PDGFRs, platelet-derived growth factor receptors
- PDX, patient-derived tumor xenograft
- PK, pharmacokinetics
- PM, pericyte medium
- Pharmacokinetic
- QC, quality control
- RE, values and relative error
- RSD, relative standard deviation
- RTKs, receptor tyrosine kinases
- TGI, tumor growth inhibition rate
- TLC, thin-layer chromatography
- Tmax, time the maximum concentration occurred
- Tumor
- ULOQ, up limit of quantitation
- VEGF, vascular endothelial growth factor
- VEGFRs, vascular endothelial growth factor receptors
- Vdss, volume of distribution at steady state
- i.v., intravenous injection
- p.o., per os
Collapse
Affiliation(s)
- Yuqin Yao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- West China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, China
| | - Zhuowei Liu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- Guangdong Raynovent Biotech Co., Ltd. Dongguan 523325, China
| | - Manyu Zhao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- West China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, China
| | | | - Peng Li
- WuXi AppTec Ltd. Shanghai 200131, China
| | | | - Yuxi Wang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
| | - Chengjian Zhao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
| | - Chaofeng Long
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- Guangdong Raynovent Biotech Co., Ltd. Dongguan 523325, China
| | - Xiaoxin Chen
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- Guangdong Raynovent Biotech Co., Ltd. Dongguan 523325, China
| | - Jinliang Yang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China
- Guangdong Zhongsheng Pharmaceutical Co., Ltd., Dongguan 523325, China
- West China School of Public Health and West China Fourth Hospital, Healthy Food Evaluation Research Center, Sichuan University, Chengdu 610041, China
| |
Collapse
|
7
|
Capella-Monsonís H, Tilbury MA, Wall JG, Zeugolis DI. Porcine mesothelium matrix as a biomaterial for wound healing applications. Mater Today Bio 2020; 7:100057. [PMID: 32577613 PMCID: PMC7305392 DOI: 10.1016/j.mtbio.2020.100057] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 05/07/2020] [Accepted: 05/08/2020] [Indexed: 12/12/2022] Open
Abstract
The increasing economic burden of wound healing in healthcare systems requires the development of functional therapies. Xenografts with preserved extracellular matrix (ECM) structure and biofunctional components overcome major limitations of autografts and allografts (e.g. availability) and artificial biomaterials (e.g. foreign body response). Although porcine mesothelium is extensively used in clinical practice, it is under-investigated for wound healing applications. Herein, we compared the biochemical and biological properties of the only two commercially available porcine mesothelium grafts (Meso Biomatrix® and Puracol® Ultra ECM) to traditionally used wound healing grafts (Endoform™, ovine forestomach and MatriStem®, porcine urinary bladder) and biomaterials (Promogran™, collagen/oxidized regenerated cellulose). The Endoform™ and the Puracol® Ultra ECM showed the highest (p<0.05) soluble collagen and elastin content. The MatriStem® had the highest (p<0.05) basic fibroblast growth factor (FGFb) content, whereas the Meso Biomatrix® had the highest (p<0.05) transforming growth factor beta-1 (TGF-β1) and vascular endothelial growth factor (VEGF) content. All materials showed tissue-specific structure and composition. The Endoform™ and the Meso Biomatrix® had some nuclei residual matter. All tissue grafts showed similar (p>0.05) response to enzymatic degradation, whereas the Promogran™ was not completely degraded by matrix metalloproteinase (MMP)-8 and was completely degraded by elastase. The Promogran™ showed the highest (p<0.05) permeability to bacterial infiltration. The Promogran™ showed by far the lowest dermal fibroblast and THP-1 attachment and growth. All tested materials showed significantly lower (p<0.05) tumor necrosis factor-alpha (TNF-α) expression than the lipopolysaccharides group. The MatriStem® and the Puracol® Ultra ECM promoted the highest (p<0.05) number of micro-vessel formation, whereas the Promogran™ the lowest (p<0.05). Collectively, these data confer that porcine mesothelium has the potential to be used as a wound healing material, considering its composition, resistance to enzymatic degradation, cytocompatibility, and angiogenic potential.
Collapse
Key Words
- Angiogenesis
- CORC-PG, collagen/oxidized regenerated cellulose—Promogran™
- Collagen devices
- DMEM, Dulbecco's modified eagle medium
- ECM, extracellular matrix
- Functional biomaterials
- HUVECs, human umbilical vein endothelial cells
- Immune response
- LB, lysogenic broth
- LPS, lipopolysaccharides
- OF-EF, ovine forestomach—Endoform™
- P/S, penicillin/streptomycin
- PBS, phosphate-buffered saline
- PFA, paraformaldehyde
- PM-MB, porcine mesothelium—Meso Biomatrix®
- PM-PC, porcine mesothelium—Puracol® Ultra ECM
- PUB-MS, porcine urinary bladder—MatriStem®
- SDS-PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis
- Xenografts
Collapse
Affiliation(s)
- H Capella-Monsonís
- Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), National University of Ireland Galway (NUI Galway), Galway, Ireland.,Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), National University of Ireland Galway (NUI Galway), Galway, Ireland
| | - M A Tilbury
- Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), National University of Ireland Galway (NUI Galway), Galway, Ireland.,Department of Microbiology, National University of Ireland Galway (NUI Galway), Galway, Ireland
| | - J G Wall
- Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), National University of Ireland Galway (NUI Galway), Galway, Ireland.,Department of Microbiology, National University of Ireland Galway (NUI Galway), Galway, Ireland
| | - D I Zeugolis
- Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), National University of Ireland Galway (NUI Galway), Galway, Ireland.,Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), National University of Ireland Galway (NUI Galway), Galway, Ireland
| |
Collapse
|
8
|
Inui A, Sekine H, Sano K, Dobashi I, Yoshida A, Matsuura K, Kobayashi E, Ono M, Shimizu T. Generation of a large-scale vascular bed for the in vitro creation of three-dimensional cardiac tissue. Regen Ther 2019; 11:316-23. [PMID: 31687425 DOI: 10.1016/j.reth.2019.10.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 09/14/2019] [Accepted: 10/01/2019] [Indexed: 12/30/2022] Open
Abstract
Introduction The definitive treatment for severe heart failure is transplantation. However, only a small number of heart transplants are performed each year due to donor shortages. Therefore, novel treatment approaches based on artificial organs or regenerative therapy are being developed as alternatives. We have developed a technology known as cell sheet-based tissue engineering that enables the fabrication of functional three-dimensional (3D) tissue. Here, we report a new technique for engineering human cardiac tissue with perfusable blood vessels. Our method involved the layering of cardiac cell sheets derived from human induced pluripotent stem cells (hiPSCs) on a vascular bed derived from porcine small intestinal tissue. Methods For the vascular bed, a segment of porcine small intestine was harvested together with a branch of the superior mesenteric artery and a branch of the superior mesenteric vein. The small intestinal tissue was incised longitudinally, and the mucosa was resected. Human cardiomyocytes derived from hiPSCs were co-cultured with endothelial cells and fibroblasts on a temperature-responsive dish and harvested as a cardiac cell sheet. A triple-layer of cardiac cell sheets was placed onto the vascular bed, and the resulting construct was subjected to perfusion culture in a bioreactor system. Results The cardiac tissue on the vascular bed pulsated spontaneously and synchronously after one day of perfusion culture. Electrophysiological recordings revealed regular action potentials and a beating rate of 105 ± 13/min (n = 8). Furthermore, immunostaining experiments detected partial connection of the blood vessels between the vascular bed and cardiac cell sheets. Conclusions We succeeded in engineering spontaneously beating 3D cardiac tissue in vitro using human cardiac cell sheets and a vascular bed derived from porcine small intestine. Further development of this method might allow the fabrication of functional cardiac tissue that could be used in the treatment of severe heart failure.
Collapse
Key Words
- 3D, three-dimensional
- Angiogenesis
- Cardiac cell sheet
- DMEM, Dulbecco's Modified Eagle Medium
- ECM, extracellular matrix
- GFP, green fluorescent protein
- HE, hematoxylin/eosin
- HUVECs, human umbilical vein endothelial cells
- NHDFs, normal human dermal fibroblasts
- PERV, porcine endogenous retrovirus
- Perfusion culture
- VEGF, vascular endothelial growth factor
- Vascular bed
- bFGF, basic fibroblast growth factor
- hiPSC, human induced pluripotent stem cells
- hiPSCs
Collapse
|
9
|
Zhou F, Mei J, Han X, Li H, Yang S, Wang M, Chu L, Qiao H, Tang T. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF- κB/MAPK signaling and protecting chondrocytes. Acta Pharm Sin B 2019; 9:973-85. [PMID: 31649847 DOI: 10.1016/j.apsb.2019.01.015] [Citation(s) in RCA: 163] [Impact Index Per Article: 32.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 11/14/2018] [Accepted: 01/28/2019] [Indexed: 12/13/2022] Open
Abstract
The objective was to investigate the effect of kinsenoside (Kin) treatments on macrophage polarity and evaluate the resulting protection of chondrocytes to attenuate osteoarthritis (OA) progression. RAW264.7 macrophages were polarized to M1/M2 subtypes then administered with different concentrations of Kin. The polarization transitions were evaluated with quantitative real-time polymerase chain reaction (qRT-PCR), confocal observation and flow cytometry analysis. The mechanism of Kin repolarizing M1 macrophages was evaluated by Western blot. Further, macrophage conditioned medium (CM) and IL-1β were administered to chondrocytes. Micro-CT scanning and histological observations were conducted in vivo on anterior cruciate ligament transection (ACLT) mice with or without Kin treatment. We found that Kin repolarized M1 macrophages to the M2 phenotype. Mechanistically, Kin inhibited the phosphorylation of IκBα, which further reduced the downstream phosphorylation of P65 in nuclear factor-κB (NF-κB) signaling. Moreover, Kin inhibited mitogen-activated protein kinases (MAPK) signaling molecules p-JNK, p-ERK and p-P38. Additionally, Kin attenuated macrophage CM and IL-1β-induced chondrocyte damage. In vivo, Kin reduced the infiltration of M1 macrophages, promoted M2 macrophages in the synovium, inhibited subchondral bone destruction and reduced articular cartilage damage induced by ACLT. All the results indicated that Kin is an effective therapeutic candidate for OA treatment.
Collapse
Key Words
- AP-1, activator protein-1
- Arg-1, arginase-1
- BV, bone volume
- BV/TV, bone volume/total tissue volume
- C/EBP β, CCAAT/enhancer-binding protein β
- CM, conditioned medium
- Chondrocytes
- DMEM, Dulbecco׳s minimum essential medium
- GA, gouty arthritis
- H&E, hematoxylin & eosin
- HUVECs, human umbilical vein endothelial cells
- IFN-γ, interferon-γ
- IRF4, interferon regulatory factor 4
- Kin, kinsenoside
- Kinsenoside
- LPS, lipopolysaccharides
- MAPK, mitogen-activated protein kinases
- MSU, monosodium urate
- Macrophages
- NF-κB, nuclear factor-κB
- NSAIDs, non-steroidal anti-inflammatory drugs
- OA, osteoarthritis
- OARSI, Osteoarthritis Research Society International
- Osteoarthritis
- PPARγ, peroxisome proliferator-activated receptor γ
- Polarization
- RA, rheumatoid arthritis
- ROS, reactive oxygen species
- S&F, safranin O-fast green
- TLRs, toll-like receptors
- TNF-α, tumor necrosis factor-α
- Tb.N, trabecular number
- Tb.Sp, trabecular separation
- Tb.Th, trabecular thickness
- iNOS, inducible nitric oxide synthase
Collapse
|
10
|
Abstract
Tenascin-C is a large, multimodular, extracellular matrix glycoprotein that exhibits a very restricted pattern of expression but an enormously diverse range of functions. Here, we discuss the importance of deciphering the expression pattern of, and effects mediated by, different forms of this molecule in order to fully understand tenascin-C biology. We focus on both post transcriptional and post translational events such as splicing, glycosylation, assembly into a 3D matrix and proteolytic cleavage, highlighting how these modifications are key to defining tenascin-C function.
Collapse
Key Words
- AD1/AD2, additional domain 1/ additional domain 2
- ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs
- ASMCs, aortic smooth muscle cells
- BDNF, brain derived neurotrophic factor
- BHKs, baby hamster kidney cells
- BMP, bone morphogenetic protein
- CA19–9, carbohydrate antigen 19–9
- CALEB, chicken acidic leucine-rich EGF-like domain containing brain protein
- CEA, carcinoembryonic antigen
- CNS, central nervous system
- CRC, colorectal carcinomas
- CTGF, connective tissue growth factor
- DCIS, ductal carcinoma in-situ
- ECM, extracellular matrix
- EDA-FN, extra domain A containing fibronectin
- EDB-FN, extra domain B containing fibronectin
- EGF-L, epidermal growth factor-like
- EGF-R, epidermal growth factor receptor
- ELISPOT, enzyme-linked immunospot assay
- FBG, fibrinogen-like globe
- FGF2, fibroblast growth factor 2
- FGF4, fibroblast growth factor 4
- FN, fibronectin
- FNIII, fibronectin type III-like repeat
- GMEM, glioma-mesenchymal extracellular matrix antigen
- GPI, glycosylphosphatidylinositol
- HB-EGF, heparin-binding EGF-like growth factor
- HCEs, immortalized human corneal epithelial cell line
- HGF, hepatocyte growth factor
- HNK-1, human natural killer-1
- HSPGs, heparan sulfate proteoglycans
- HUVECs, human umbilical vein endothelial cells
- ICC, immunocytochemistry
- IF, immunofluorescence
- IFNγ, interferon gamma
- IGF, insulin-like growth factor
- IGF-BP, insulin-like growth factor-binding protein
- IHC, immunohistochemistry
- IL, interleukin
- ISH, in situ hybridization
- LPS, lipopolysaccharide
- MMP, matrix metalloproteinase
- MPNSTs, malignant peripheral nerve sheath tumors
- Mr, molecular mass
- NB, northern blot
- NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells
- NK, natural killer cells
- NSCLC, non-small cell lung carcinoma
- NSCs, neural stem cells
- NT, neurotrophin
- PAMPs, pathogen-associated molecular patterns
- PDGF, platelet derived growth factor
- PDGF-Rβ, platelet derived growth factor receptor β
- PIGF, phosphatidylinositol-glycan biosynthesis class F protein
- PLCγ, phospholipase-C gamma
- PNS, peripheral nervous system
- PTPRζ1, receptor-type tyrosine-protein phosphatase zeta
- RA, rheumatoid arthritis
- RCC, renal cell carcinoma
- RD, rhabdomyosarcoma
- RGD, arginylglycylaspartic acid
- RT-PCR, real-time polymerase chain reaction
- SB, Southern blot
- SCC, squamous cell carcinoma
- SMCs, smooth muscle cells
- SVZ, sub-ventricular zone
- TA, tenascin assembly domain
- TGFβ, transforming growth factor β
- TIMP, tissue inhibitor of metalloproteinases
- TLR4, toll-like receptor 4
- TNFα, tumor necrosis factor α
- TSS, transcription start site
- UBC, urothelial bladder cancer
- UCC, urothelial cell carcinoma
- VEGF, vascular endothelial growth factor
- VSMCs, vascular smooth muscle cells
- VZ, ventricular zone
- WB, immunoblot/ western blot
- bFGF, basic fibroblast growth factor
- biosynthesis
- c, charged
- cancer
- ccRCC, clear cell renal cell carcinoma
- chRCC, chromophobe-primary renal cell carcinoma
- development
- glycosylation
- mAb, monoclonal antibody
- matrix assembly
- mitogen-activated protein kinase, MAPK
- pHo, extracellular pH
- pRCC, papillary renal cell carcinoma
- proteolytic cleavage
- siRNA, small interfering RNA
- splicing
- tenascin-C
- therapeutics
- transcription
Collapse
Affiliation(s)
- Sean P Giblin
- a Nuffield Department of Orthopaedics; Rheumatology and Musculoskeletal Sciences ; Kennedy Institute of Rheumatology; University of Oxford ; Oxford , UK
| | | |
Collapse
|
11
|
Huang S, Li H, Ge J. A cardioprotective insight of the cystathionine γ-lyase/hydrogen sulfide pathway. Int J Cardiol Heart Vasc 2015; 7:51-57. [PMID: 28785645 PMCID: PMC5497180 DOI: 10.1016/j.ijcha.2015.01.010] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2014] [Revised: 11/29/2014] [Accepted: 01/20/2015] [Indexed: 11/29/2022]
Abstract
Traditionally, hydrogen sulfide (H2S) was simply considered as a toxic and foul smelling gas, but recently H2S been brought into the spot light of cardiovascular research and development. Since the 1990s, H2S has been mounting evidence of physiological properties such as immune modification, vascular relaxation, attenuation of oxidative stress, inflammatory mitigation, and angiogenesis. H2S has since been recognized as the third physiological gaseous signaling molecule, along with CO and NO [65,66]. H2S is produced endogenously through several key enzymes, including cystathionine β-lyase (CBE), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (MST)/cysteine aminotransferase (CAT). These specific enzymes are expressed accordingly in various organ systems and CSE is the predominant H2S-producing enzyme in the cardiovascular system. The cystathionine γ-lyase (CSE)/H2S pathway has demonstrated various cardioprotective effects, including anti-atherosclerosis, anti-hypertension, pro-angiogenesis, and attenuation of myocardial ischemia-reperfusion injury. CSE exhibits its anti-atherosclerotic effect through 3 mechanisms, namely reduction of chemotactic factor inter cellular adhesion molecule-1 (ICAM-1) and CX3CR1, inhibition of macrophage lipid uptake, and induction of smooth muscle cell apoptosis via MAPK pathway. The CSE/H2S pathway's anti-hypertensive properties are demonstrated via aortic vasodilation through several mechanisms, including the direct stimulation of KATP channels of vascular smooth muscle cells (VSMCs), induction of MAPK pathway, and reduction of homocysteine buildup. Also, CSE/H2S pathway plays an important role in angiogenesis, particularly in increased endothelial cell growth and migration, and in increased vascular network length. In myocardial ischemia-reperfusion injuries, CSE/H2S pathway has shown a clear cardioprotective effect by preserving mitochondria function, increasing antioxidant production, and decreasing infarction injury size. However, CSE/H2S pathway's role in inflammation mitigation is still clouded, due to both pro and anti-inflammatory results presented in the literature, depending on the concentration and form of H2S used in specific experiment models.
Collapse
Key Words
- Akt, protein kinase B
- Angiogenesis
- Atherosclerosis
- BCA, brachiocephalic artery
- CAM, chorioallantoic membrane
- CAT, cysteine aminotransferase
- CBS, cystathionine β-lyase
- CLP, cecal ligation and puncture
- CSE KO, CSE knock out
- CSE, cystathionine γ-lyase
- CTO, chronic total occlusion
- CX3CL1, chemokine (C-X3-C Motif) ligand 1
- CX3CR1, CX3C chemokine receptor 1
- Cystathionine γ-lyase
- EC, endothelial cell
- ERK, extracellular signal-regulated kinase
- GAPDH, glyceraldehyde 3-phosphate dehydrogenase
- GSH-Px, glutathione peroxidase
- GYY4137, morpholin-4-Ium-4-methoxyphenyl(morpholino) phosphinodithioate
- H2S, hydrogen sulfide
- HUVECs, human umbilical vein endothelial cells
- Hydrogen sulfide
- ICAM-1, inter cellular adhesion molecule-1
- IMT, intima–media complex thickness
- Ischemia–reperfusion injury
- LPS, lipopolysaccharide
- MAPK, mitogen-activated protein kinase
- MPO, myeloperoxidase
- MST, 3-mercaptopyruvate sulfurtransferase
- NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells
- Nrf2, nuclear factor erythroid 2-related factor 2
- PAG, DL-propagylglycine
- PPAR-γ, peroxisome proliferator-activated receptor
- PTPN1, protein tyrosine phosphatase, non-receptor type 1
- ROS, reactive oxygen species
- S-diclofenac, 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(3H-1,2-dithiole-3-thione-5-Yl)-phenyl ester
- SAH, S-adenosylhomocysteine
- SAM, S-adenosylmethionine
- SMCs, smooth muscle cells
- SOD, superoxide dismutase
- VEGF, vascular endothelial growth factor
- VSMCs, vascular smooth muscle cells
- Vasorelaxation
- l-NAME, NG-nitro-l-arginine methyl ester
- oxLDL, oxidized low density lipoprotein
Collapse
Affiliation(s)
- Steve Huang
- Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Hua Li
- Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Departments of Physiology and Medicine/CVRL, UCLA School of Medicine, Los Angeles, CA 90095, USA
| | - Junbo Ge
- Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
| |
Collapse
|
12
|
Zhao S, Liao H, Ao M, Wu L, Zhang X, Chen Y. Fixation-induced cell blebbing on spread cells inversely correlates with phosphatidylinositol 4,5-bisphosphate level in the plasma membrane. FEBS Open Bio 2014; 4:190-9. [PMID: 24649401 DOI: 10.1016/j.fob.2014.02.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Revised: 02/07/2014] [Accepted: 02/10/2014] [Indexed: 12/15/2022] Open
Abstract
Protein- but not lipid-stabilizing fixatives induce cell blebbing of spread cells. Asymmetric distribution of fixation-induced blebs coincides with that of PIP2. Fixation less readily induces blebbing on spread cells with elevated PIP2 levels. Fixation more readily induces blebbing on spread cells with lower PIP2 levels. Disruption of lipid rafts enhances fixation-induced blebbing of spread cells.
While most attention has been focused on physiologically generated blebs, the molecular mechanisms for fixation-induced cell blebbing are less investigated. We show that protein-fixing (e.g. aldehydes and picric acid) but not lipid-stabilizing (e.g. OsO4 and KMnO4) fixatives induce blebbing on spread cells. We also show that aldehyde fixation may induce the loss or delocalization of phosphatidylinositol 4,5-bisphosphate (PIP2) in the plasma membrane and that the asymmetric distribution of fixation-induced blebs on spread/migrating cells coincides with that of PIP2 on the cells prefixed by lipid-stabilizing fixatives (e.g., OsO4). Moreover, fixation induces blebbing less readily on PIP2-elevated spread cells but more readily on PIP2-lowered or lipid raft-disrupted spread cells. Our data suggest that fixation-induced lowering of PIP2 level at cytoskeleton-attaching membrane sites causes bleb formation via local breakdown of the membrane–cytoskeleton coupling.
Collapse
Key Words
- Cell blebbing
- Cell fixation
- DAG, 1,2-diacylglycerol
- DIC, differential interference contrast
- HUVECs, human umbilical vein endothelial cells
- Human umbilical vein endothelial cells (HUVECs)
- IP3, inositol 1,4,5-trisphosphate
- Lipid rafts
- MβCD, methyl-β-cyclodextrin
- PI3K, phosphoinositide-3 kinase
- PIP2, phosphatidylinositol 4,5-bisphosphate
- PIP3, phosphatidylinositol 3,4,5-trisphosphate
- PLC, phospholipase C
- Phosphatidylinositol 4,5-bisphosphate (PIP2)
- TBS, Tris-buffered saline
- THP-1-derived macrophages
Collapse
|